GRFS
GRIFOLS·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Cash/net Profit Ratio
Bullish Abandoned Baby
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GRFS
Grifols, S.A.
The Europe's largest plasma products company
Biological Technology
--
06/02/2011
NASDAQ Stock Exchange
23,822
12-31
Depository Receipts (Ordinary Shares)
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles 08174, Barcelona, Spain
--
GRIFOLS, S.A. is a global healthcare company with products sold in more than 100 countries and directly affiliated institutions in more than 30 countries. The company's Class A shares have been listed on the Spanish Stock Exchange (MCE: GRF) since 2006 and became a constituent of the IBEX 35 Index in 2008. In 2011, the company issued non-voting Class B shares through American Depositary Receipts (ADRs) on the Spanish Stock Exchange (MCE: GRF.P) and Nasdaq (GRFS) in the United States. Griffalls has become one of the largest plasma companies in the world and has expanded and diversified its plasma sources in recent years by establishing a strong network of plasma donation centers in the United States, Europe, Egypt and Canada. Griffiles uses the acquired plasma to produce important drugs for the treatment of chronic, rare and some very serious diseases. As a recognized leader in the field of blood transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from blood donation to blood transfusion. In addition, the company supplies biological products for non-therapeutic uses. Grifols has the necessary infrastructure and experience to plan for future needs and maintain sustainability through continuous improvement and process and cost optimization. Its strong production bases, mainly located in the United States and Spain, enable it to expand its large-scale, global business and meet the growing market demand.
Company Financials
EPS
GRFS has released its 2022 Q2 earnings. EPS was reported at 0.14, versus the expected 0, beating expectations. The chart below visualizes how GRFS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GRFS has released its 2025 Q3 earnings report, with revenue of 2.19B, reflecting a YoY change of 9.55%, and net profit of 168.31M, showing a YoY change of 84.22%. The Sankey diagram below clearly presents GRFS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
